In this article, based on literature review, we present an integrated description of heboidophrenia and pseudo-psychopathic schizophrenia. Both diagnostic constructs describe latent psychotic processes inextricably bound with psychopathic features. Although both have been described in different eras and research threads, they are that similar that we could not find divergences. We formulated operational criteria for clinical and research purpose. The recognition of this syndrome improves risk management, treatment, and legal decisions.

1.
Kahlbaum K: On heboidophrenia. Allg Z Für Psychiatr 1890; 46: 461–471.
2.
Dunaif S, Hoch PH: Pseudopsychopathic schizophrenia; in Psychiatry and The Law. New York, Grune & Stratton, 1954, pp 169–195.
3.
Hare RD: The Hare Psychopathy Checklist-Revised: Manual. Toronto, Multi-Health Systems, Inc., 1991.
4.
Cooke DJ, Hart SD, Logan C, Michie C: Explicating the construct of psychopathy: development and validation of a conceptual model, the Comprehensive Assessment of Psychopathic Personality (CAPP). Int J Forensic Ment Health 2012; 11: 242–252.
5.
Coulon N, Walter M: L’héboïdophrénie, un diagnostic oublié? Rev Francaise Psychiatr Psychol Méd 2006; 10: 29–34.
6.
Garrabé J: Schizophrénies et héboïdophrénie. Evol Psychiatr (Paris) 2001; 66: 609–613.
7.
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research, 1993.
8.
Ey H, Bernard P, Brisset C: Manuel de Psychiatrie, 1972.
9.
Garrabé J: Note historique sur l’héboïdophrénie. Evol Psychiatr (Paris) 1996; 61: 75–85.
10.
Guiraud P: Constitution perverse ou héboïdophrénie. Bull Soc Clin de Med Ment 1927; 89–92.
11.
Guiraud P: Les meurtres immotivés. LÉvolution Psychiatr 1931; 4: 25–34.
12.
Soccaras E: Schizophrénie pseudo-névrotique et schizophrénie caracterielle. Rev Fr Psychanal 1957; 21: 535–552.
13.
Foullu S, Estingoy P: De l’intérêt clinique du concept d’héboïdophrénie. À propos de deux cas de schizophrénie criminelle. Ann Méd-Psychol Rev Psychiatr 2006; 164: 756–763.
14.
Kaplan H: The schizophrenic reaction with psychopathic features: clinical characteristics and response to therapy: a comprehensive study of seven cases. AMA Arch Neurol Psychiatry 1952; 68: 258–265.
15.
Stephens JH, Astrup C: Prognosis in “process” and “non-process” schizophrenia. Am J Psychiatry 1963; 119: 945–953.
16.
Geller MP: Sociopathic adaptations in psychotic patients. Psychiatr Serv 1980; 31: 108–112.
17.
Kraam A, Berrios G: On Heboïdophrenia. Hist Psychiatry 2002; 13: 197–208.
18.
Stanghellini G: Psychopathological roots of early schizophrenia: adolescent vulnerability, hebephrenia and heboidophrenia. Curr Opin Psychiatry 2004; 17: 471–477.
19.
Carraz YC: L’héboïdophrénie, 1968.
20.
Halberstadt G: La forme héboïdophrénique de la démence précoce. Ann Méd Psychol 1925;II: 23–32.
21.
Benon R: Démence précoce et vagabondage. Ann Hygiène Publique Médecine Légale 1923; 4: 90–96.
22.
Durst R, Jabotinsky-Rubin K, Fliman M: Pseudopsychopathic schizophrenia – a neglected diagnostic entity with legal implications. Med L 1997; 16: 487–498.
23.
Haustgen T: Le concept clinique d’héboïdophrénie; in Masson M (ed): 24 Textes Fondateurs de la Psychiatrie Introduits et Commentés par la Société Médico-Psychologique. Paris, Armand Colin, 2013.
24.
Rinderknecht G: Über kriminelle Heboide. Z Für Gesamte Neurol Psychiatr 1920; 57: 35–70.
25.
Bender L: The concept of pseudopsychopathic schizophrenia in adolescents. Am J Orthopsychiat 1959; 29: 491–512.
26.
Heuyer MG, Serin: Les troubles du caractère au début de la démence précoce. Ann Méd Psychol 1930; 2: 90–110.
27.
Capgras, Dupouy, Briau: Délire malicieux héboïdophrénique. Ann Méd-Psychol 1927; 2: 360–372.
28.
Guttmacher M: Pseudopsychopathic schizophrenia. Arch Crim Psychodyn Spec Psychopathy Issue 1961; 502–508.
29.
Chazaud J: Hystérie, Schizophrénie, Paranoïa: Chemins Vers une Psychiatrie Psychanalytique. Toulouse, Privat, 1983.
30.
De Page L, Titeca P: Psychopathy and Psychosis: A Hazardous Interplay and Questionnable Treatment, 2014.
31.
Volavka J, Citrome L: Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract 2008; 62: 1237–1245.
32.
Trull TJ, Jahng S, Tomko RL, Wood PK, Sher KJ: Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Personal Disord 2010; 24: 412–426.
33.
Henderson MC, Kalichman SC: Sexually deviant behavior and schizotypy: a theoretical perspective with supportive data. Psychiatr Q 1990; 61: 273–284.
34.
de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H: The facts about sexual (dys) function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull 2015; 41: 674–686.
35.
Claude H, Minkowski E, Tison: Contribution à l’étude des mécanismes schizophréniques. L’Encéphale 1925; 2–13.
36.
Kernberg: Diagnóstico diferencial de la conducta antisocial. Rev Psiquiatr Chile 1988; 5: 101–111.
37.
De Page L, Englebert J: Réflexion Psychopathologique Sur le Diagnostic D’héboïdophrénie, 2016.
38.
Bird G, Viding E: The self to other model of empathy: providing a new framework for understanding empathy impairments in psychopathy, autism, and alexithymia. Neurosci Biobehav Rev 2014; 47: 520–532.
39.
Henry J, Pingault J-B, Boivin M, Rijsdijk F, Viding E: Genetic and environmental aetiology of the dimensions of Callous-Unemotional traits. Psychol Med 2016; 46: 405–414.
40.
Frick PJ, Ray JV, Thornton LC, Kahn RE: Can callous-unemotional traits enhance the understanding, diagnosis, and treatment of serious conduct problems in children and adolescents? A comprehensive review. Psychol Bull 2014; 140: 1–57.
41.
Muratori P, Lochman JE, Manfredi A, Milone A, Nocentini A, Pisano S, et al: Callous unemotional traits in children with disruptive behavior disorder: predictors of developmental trajectories and adolescent outcomes. Psychiatry Res 2016; 236: 35–41.
42.
Tengström A, Grann M, Langström N, Kullgren G: Psychopathy (PCL-R) as a predictor of violent recidivism among criminal offenders with schizophrenia. Law Hum Behav 2000; 24: 45–58.
43.
Biéder J, Callens H, Alcalay J: À propos du vol “normal” et pathologique. Ann Méd-Psychol 2001; 159: 131–139.
44.
Fullam R, Dolan M: The criminal and personality profile of patients with schizophrenia and comorbid psychopathic traits. Personal Individ Differ 2006; 40: 1591–1602.
45.
Holmesland P, Astrup C: Pseudoneurotic and pseudopsychopathic schizophrenia: a follow-up. Neuropsychobiology 1984; 12: 101–105.
46.
Dubret G: Quel cadre de soin pour les psychopathes? Evol Psychiatr (Paris) 2001; 66: 665–668.
47.
Kernberg OF: Perversion, perversity, and normality: diagnostic and therapeutic considerations. Perversion Psychoanal Perspect Perspect Psychoanal 2006; 19–38.
48.
Coté G, Hodgins S: Co-occurring mental disorders among criminal offenders. J Am Acad Psychiatry Law Online 1990; 18: 271–281.
49.
Gosden NP, Kramp P, Gabrielsen G, Andersen TF, Sestoft D: Violence of young criminals predicts schizophrenia: a 9-year register-based followup of 15-to 19-year-old criminals. Schizophr Bull 2005; 31: 759–768.
50.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision), 2000.
51.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Arlington, American Psychiatric Pub, 2013.
52.
Zagury D: Place et évolution de la fonction de l’expertise psychiatrique. Psychopathol Trait Actuels Auteurs D’Agression Sex, 2001.
53.
De Page L, Matteucci M, Englebert J: The shortcomings of the Psychopathy Checklist-Revised (PCL-R) in a forensic schizophrenic sample. Ann Méd-Psychol, in-press.
54.
Englebert J: A new understanding of psychopathy: the contribution of phenomenological psychopathology. Psychopathology 2015; 48: 368–375.
55.
Tengström A, Hodgins S, Grann M, LÅngstrÖm N, Kullgren G: Schizophrenia and criminal offending the role of psychopathy and substance use disorders. Crim Justice Behav 2004; 31: 367–391.
56.
Meggendorfer F: Klinische und genealogische Untersuchungen über “Moral insanity.” Z Für Gesamte Neurol Psychiatr 1921; 66: 208–231.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.